The present invention provides a compound of the formula (I) wherein R.sup.1 is --H, --OH, --O(C.sub.1-C.sub.4 alkyl), --OCOC.sub.6H.sub.5, --OCO(C.sub.1-C.sub.6 alkyl), or --OSO.sub.2(C.sub.2-C.sub.6 alkyl); R.sup.0, R.sup.2 and R.sup.3 are each independently --H, --OH, --O(C.sub.1-C.sub.4 alkyl), --OCOC.sub.6H.sub.5, --OCO(C.sub.1-C.sub.6 alkyl), --OSO.sub.2(C.sub.2-C.sub.6 alkyl) or halo; R.sup.4 is 1-piperidinyl, 1-pyrrolidinyl, methyl- 1-pyrrolidinyl, dimethyl-1-pyrrolidiny, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n is 2 or 3 X is --S-- or --HC.dbd.CH--; G is --O--, --S--, --SO--, SO.sub.2, or --N(R.sup.5)--, wherein R.sup.5 is --H or C.sub.1-C.sub.4 alkyl; and Y is --O--, --S--, --NH--, --NMe--, or --CH.sub.2--; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions thereof, optionally in combination with estrogen and progestin; methods of inhibiting a disease associated with estrogen deprivation; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.